News

The yield on the 2-year US Treasury fell by 2.70 basis points to 4.1101%, remaining in a downward trend throughout the day, trading within the range of 4.1350%-4.1018%. The yield on the 30-year US Treasury fell by 0.10 basis points to 4.9844%. The spread between the 2-year and 10-year US Treasury yields widened by 1.103 basis points to +35.506 basis points. The yield on the 10-year Treasury Inflation-Protected Securities (TIPS) dropped by 2.41 basis points to 2.2161%; the 2-year TIPS yield decreased by 3.05 basis points to 2.1295%; the 30-year TIPS yield declined by 0.37 basis points to 2.7962%.

At the same time, the company provided an update on the progress of its financial reporting for the first quarter of 2026. By removing the variable conversion clause from its debt instruments, Cloudastructure has effectively reduced the risk of future equity dilution and improved the stability of its financial structure. This adjustment is expected to give the company greater financial flexibility to support its long-term strategic development. In addition, regarding financial reporting for the first quarter of 2026, the company confirmed that relevant preparations are progressing as planned and that it will ensure the timely disclosure of complete financial information to the market. This move further demonstrates Cloudastructure's commitment to transparency and compliance.

The document clarifies the specific circumstances that would trigger this substantial financial obligation. The terms of the agreement show that payment of this fee does not take effect automatically and is closely tied to specific termination conditions. This provides market participants and investors with key details about the financial arrangements behind this potential collaboration.Analysts point out that termination fee clauses of such a large amount are typically intended to safeguard the significant interests of both parties, especially in major strategic partnerships or acquisition negotiations. They not only demonstrate the seriousness and depth of commitment to the deal, but may also reflect the high value and expectations both sides place on its ultimate completion. However, this also means that if the agreement falls through under the stipulated conditions, Crinetics Pharmaceuticals would face significant financial outlays.Currently, the market is closely watching the latest developments from both companies and the specific progress of the deal. The disclosure of such financial arrangement details helps investors more comprehensively assess the risks and potential impacts of the related transaction.